2025-02-15
Semaglutide is a hypoglycemic drug developed by Novo Nordisk. The drug is a glucagon-like peptide-1 receptor
agonist (GLP-1RA) that is effective in weight loss because it reduces hunger, which leads to a lower diet and reduced
caloric intake.
In addition to being used to treat type 2 diabetes and obesity, semaglutide has also been found to protect
cardiovascular health, reduce cancer risk, reduce the risk of Alzheimer's disease, help with alcohol abstinence, and
much more.
